文献速递慢病防控与筛查免疫规划

针对乳腺癌和卵巢癌CA-125新抗原的计算机设计mRNA疫苗

In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer.
PubMed 文献 · Vaccine · 2023-02-20

本研究利用免疫生物信息学工具,基于乳腺癌或卵巢癌中CA-125的体细胞突变驱动新抗原预测细胞毒性CD8+ T细胞表位,构建了携带CD40L和MHC-I靶向结构域的自佐剂mRNA疫苗,并用计算机ImmSim算法估计免疫后产生IFN-γ和CD8+ T细胞应答,该策略可能可扩展用于设计靶向多种新抗原的精准多表位mRNA疫苗。

要点

  • 基于CA-125体细胞突变新抗原预测CD8+ T细胞表位。
  • 构建含CD40L和MHC-I靶向结构域的自佐剂mRNA疫苗。
  • 计算机模拟显示免疫后IFN-γ和CD8+ T细胞应答。

核心结论

  • 本研究描述的策略可能可扩展并实施,用于通过靶向多种新抗原设计精准多表位mRNA疫苗。

研究设计与样本

  • 计算机设计流程,针对乳腺癌和卵巢癌分别设计CA-125新抗原mRNA疫苗。

主要发现

  • 基于乳腺癌或卵巢癌中CA-125的体细胞突变驱动新抗原预测了细胞毒性CD8+ T细胞表位。
  • 构建了携带CD40L和MHC-I靶向结构域的自佐剂mRNA疫苗,以增强树突状细胞对新表位的交叉呈递。
  • 用计算机ImmSim算法估计免疫后应答,显示IFN-γ和CD8+ T细胞应答。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Somatic mutation-derived neoantigens are associated with patient survival in breast and ovarian cancer. These neoantigens are targets for cancer, as shown by the implementation of neoepitope peptides as cancer vaccines. The success of cost-effective multi-epitope mRNA vaccines against SARS-Cov-2 in the pandemic established a model for reverse vaccinology. In this study, we aimed to develop an in silico pipeline designing an mRNA vaccine of the CA-125 neoantigen against breast and ovarian cancer, respectively. Using immuno-bioinformatics tools, we predicted cytotoxic CD8+ T cell epitopes based on somatic mutation-driven neoantigens of CA-125 in breast or ovarian cancer, constructed a self-adjuvant mRNA vaccine with CD40L and MHC-I -targeting domain to enhance cross-presentation of neoepitopes by dendritic cells. With an in silico ImmSim algorithm, we estimated the immune responses post-immunization, showing IFN-γ and CD8+ T cell response. The strategy described in this study may be scaled up and implemented to design precision multi-epitope mRNA vaccines by targeting multiple neoantigens.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lu L, Ma W, Johnson CH, et al. In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer. Vaccine. 2023. PMID: 36813666. doi:10.1016/j.vaccine.2023.02.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。